Epigenic Therapeutics, a clinical-stage biotech company specializing in epigenetic-based drug development, has secured $60 million in a Series B funding round. The round was led by Lapam Capital and included continued support from previous investors Qiming Venture Partners and OrbiMed, as well as new participants such as IFSC and a prominent life sciences investment firm. The funds will primarily support the clinical advancement of EPI-003, aimed at a functional cure for chronic hepatitis B, and EPI-001, designed to treat high cholesterol. Additionally, the financing will accelerate multiple preclinical projects and enhance the company’s technology platforms, reinforcing Epigenic’s commitment to developing innovative epigenetic therapies.
Epigenic is recognized for its next-generation gene modulation therapies that modify the epigenome to address widespread diseases. Their proprietary EPIREG platform enables targeted, durable, and precise gene silencing by altering DNA methylation and histone modifications. Unlike traditional gene-editing methods that cut DNA, this approach offers a safer alternative for patients with chronic conditions by minimizing safety risks commonly associated with DNA cleavage.
Health Technology Insights: FDA Reviews Shionogi’s COVID-19 Prevention Pill NDA as the First Oral Therapy
The company has also developed EpiTax, an in-vivo lipid nanoparticle delivery system that efficiently transports EPIREG tools not only to the liver but to other organs as well. This expanded delivery capacity broadens the potential applications of their technology and strengthens Epigenic’s competitive advantage in the field of epigenetic medicine.
Furthermore, Epigenic’s AIAID platform supports the design and precise regulation of epigenetic therapies. It incorporates a proprietary foundational epigenetic model that delivers accurate data and algorithms. The platform includes an autonomous virtual lab capable of handling tasks such as target discovery, gene accessibility evaluation, sgRNA design, epigenetic modification simulation, and multi-omics analysis. Additionally, it leverages artificial intelligence to accelerate new protein design and evolution, enhancing the development of the EPIREG platform.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 2 September 2025
Dr. Bob Zhang, Co-founder and CEO of Epigenic Therapeutics, expressed gratitude to both new and returning investors for their support. He highlighted the company’s rapid progress in advancing epigenetic modulation technologies and emphasized their ongoing commitment to delivering safe and effective treatments to patients as quickly as possible. Zhihua Yu, Chairman of Lapam Capital, praised the potential of epigenetic drug development and commended Epigenic’s leadership and growth prospects. He noted that the combination of the EPIREG platform with the EpiTax delivery system forms a powerful therapeutic solution and expressed confidence that the new funding will accelerate clinical and technological breakthroughs, solidifying Epigenic’s position as a leader in the field and bringing transformative therapies to patients worldwide.
Health Technology Insights: Predicine Submits PMA for Bladder Cancer Companion Diagnostic Assay
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
